Cartesian Therapeutics (RNAC) Payables (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Payables of $1.6 million for Q1 2026, down 23.8% year-over-year from $2.1 million in Q1 2025, and up 24.07% quarter-over-quarter from $1.3 million in Q4 2025.
Cartesian Therapeutics (RNAC) Payables (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Payables for 12 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 23.8% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 23.8% YoY), while the FY2025 annual figure was $1.3 million, up 347.22% from the prior year.
- Payables rose to $1.6 million in Q1 2026 per RNAC's latest filing, from $1.3 million in the prior quarter.
- Across five years, Payables topped out at $31.5 million in Q4 2023 and bottomed at $214000.0 in Q3 2022.
- Historically, Payables has averaged $2.9 million across 5 years, with a median of $693000.0 in 2022.
- Annual changes were most pronounced in 2023 — Payables jumped 9854.75% — and 2024, when it tumbled 99.08%.
- Cartesian Therapeutics' Payables stood at $316000.0 in 2022, then surged by 9854.75% to $31.5 million in 2023, then sank by 99.08% to $288000.0 in 2024, then jumped by 347.22% to $1.3 million in 2025, then advanced by 24.07% to $1.6 million in 2026.
- Business Quant data shows RNAC's Payables at $1.6 million in Q1 2026, $1.3 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 1.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.05 Mn |
| Mar 31, 2026 | 1.60 Mn |
| Dec 31, 2025 | 1.29 Mn |
| Sep 30, 2025 | 2.23 Mn |
| Jun 30, 2025 | 454,000.00 |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 288,000.00 |
| Sep 30, 2024 | 517,000.00 |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | 2.52 Mn |
| Dec 31, 2023 | 31.46 Mn |
| Sep 30, 2023 | 375,000.00 |
| Jun 30, 2023 | 267,000.00 |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 316,000.00 |
| Sep 30, 2022 | 214,000.00 |
| Jun 30, 2022 | 693,000.00 |
| Mar 31, 2022 | 264,000.00 |
| Dec 31, 2021 | 224,000.00 |
| Sep 30, 2021 | 1.59 Mn |